Incyte (INCY) 12th Annual Cantor Fitzgerald Global Healthcare Conference summary

Strategic progress and business outlook

• Pipeline advanced from proof-of-concept to multiple phase III programs, providing visibility into post-2029 growth after Jakafi loss.

• Core business targets $3–$4 billion, supported by new launches and upcoming approvals over the next 12–18 months.

• Five key assets expected to drive 80% of recovery, with execution focused on regulatory approvals and revenue conversion.

• Business development will supplement internal growth, prioritizing accretive opportunities post-2029.

• Guidance on trough earnings and recovery expected next year as more data emerges.

Financial management and investment priorities

• Top quartile growth targeted, aiming for 15–20% CAGR from 2023 to 2035, with potential to double the business.

• Capital allocation prioritizes maximizing phase III R&D programs, especially INCA033989 and G12D.

• Selective business development, exemplified by the Star Therapeutics deal, focuses on late-stage, de-risked assets.

• R&D investment is highly focused, with over 80% directed at key pipeline assets.

• Ongoing evaluation of projects ensures resources are allocated to high-value opportunities.

Pipeline highlights and clinical updates

• G12D (734) program in pancreatic and colorectal cancer to present expanded efficacy and safety data at ESMO; phase III trial enrolling globally.

• Combination strategies and external collaborations for 734 are in progress, with more details expected soon.

• GI adverse events with 734 improve after the first cycle, with prophylaxis measures incorporated into phase III.

• TGFβR2xPD-1 bispecific in MSS colorectal cancer to show promising response rates at ESMO, supporting a global phase III study.